×
Bavarian Nordic Operating Expenses 2016-2024 | BVNRY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Bavarian Nordic operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Bavarian Nordic Operating Expenses 2016-2024 | BVNRY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Bavarian Nordic operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.8B
Vertex Pharmaceuticals (VRTX)
$133.1B
Gilead Sciences (GILD)
$120.2B
Bristol Myers Squibb (BMY)
$109.8B
Regeneron Pharmaceuticals (REGN)
$91B
CSL (CSLLY)
$90.5B
GSK (GSK)
$75.2B
Alnylam Pharmaceuticals (ALNY)
$35.8B
Argenex SE (ARGX)
$35.6B
BioNTech SE (BNTX)
$26.3B
Biogen (BIIB)
$25.2B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$18B
Incyte (INCY)
$16.1B
Genmab (GMAB)
$15.3B
Vaxcyte (PCVX)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.6B
Exelixis (EXEL)
$10.4B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B